vosaroxin

Vosaroxin is a first-in-class small molecule anticancer quinolone derivative (naphthyridine analogue) with antineoplastic activity, primarily developed for the treatment of acute myeloid leukemia (AML). Its mechanism of action involves intercalating into DNA at GC-rich regions and inhibiting topoisomerase II, which blocks the re-ligation process during DNA replication. This leads to site-selective double-strand DNA breaks, cell cycle arrest at the G2/M phase, and apoptosis in tumor cells. Vosaroxin is distinct from other topoisomerase II inhibitors due to its quinolone scaffold, reduced generation of reactive oxygen species (lowering cardiotoxicity risk), lack of P-glycoprotein substrate activity (evading common multidrug resistance mechanisms), and p53-independent activity. It has been evaluated in phase III clinical trials for relapsed/refractory AML and investigated for ovarian cancer[1][3][4][5][6][7][8].

Brand names

Qinprezo

Other names

voreloxinvosaroxin